Literature DB >> 26730314

Prevalence and Causes of Visual Impairment and Blindness in Central Iran; The Yazd Eye Study.

Marzieh Katibeh1, Mohammad Pakravan2, Mehdi Yaseri3, Mojgan Pakbin1, Reza Soleimanizad4.   

Abstract

PURPOSE: To determine the prevalence and causes of blindness and visual impairment (VI) in Yazd, central Iran.
METHODS: This population-based, cross-sectional study was performed on adults aged 40-80 years, residing in Yazd district, in 2010-2011. Eligible subjects were selected using cluster random sampling. Each participant underwent an interview and complete ophthalmologic examination. Blindness and VI were defined as best-corrected visual acuity (VA) <3/60 and < 6/18 in the better eye, respectively.
RESULTS: Out of 2,320 eligible individuals, 2,098 participated in the study (90.4% response rate), of whom, 2,023 subjects completed all evaluations. The standardized prevalence of blindness and VI were 0.7% (95% confidence interval [CI], 0.3-1.0%) and 4.4% (95% CI, 3.3-5.4%), respectively which was significantly associated with older age (odd ratio [OR] = 3.2, 95% CI: 1.9-5.2 and OR = 3.1, 95% CI: 2.3-4.2, respectively) and female sex (OR = 3.6, 95% CI: 1.1-12.3 and OR = 1.7, 95% CI: 1.2-2.5, respectively). The proportion of avoidable causes of blindness and VI were 92.9% (95% CI: 80.0-100.0%) and 76.6% (95% CI: 69.2-85.0%), respectively. Major causes of blindness were diabetic retinopathy (50.0%), glaucoma (21.4%) and cataracts (14.3%) whereas main causes of VI were cataracts (41.5%), diabetic retinopathy (17.0%) and age-related macular degeneration (13.8%).
CONCLUSIONS: Diabetic retinopathy, glaucoma, cataract and age-related macular degeneration were the leading causes of blindness and VI in Yazd, most of which are avoidable. Planning for prevention of blindness is highly recommended to decrease the proportion of avoidable blindness.

Entities:  

Keywords:  Blindness; Community Health Planning; Iran; Prevalence

Year:  2015        PMID: 26730314      PMCID: PMC4687262          DOI: 10.4103/2008-322X.170362

Source DB:  PubMed          Journal:  J Ophthalmic Vis Res        ISSN: 2008-322X


INTRODUCTION

Visual impairment (VI) is a major health problem worldwide.[1] According to the World Health Organization (WHO) estimations, 285 million visually impaired people lived in the world in 2010 which included 39 million blind people and 246 million subjects with low vision.[2] Visual problems impose large costs on the society.[3] Nowadays, living standards have been improved in most communities, but the prevalence of avoidable blindness remains significantly high in many countries. Almost 80% of global VI is treatable or preventable.[1] Cataracts and uncorrected refractive errors have been accounted as the leading causes of VI, and the major cause of blindness is cataract.[2] Data on the prevalence and causes of VI and blindness is required to plan programs for eliminating avoidable blindness and VI. About 90% of the world's visually impaired subjects, live in developing countries.[14] A number of studies have reported the prevalence of VI and blindness in Iran, but no population-based study data is available from central Iran.[56789] This population-based study was performed in Yazd district to determine the prevalence and causes of VI and blindness in the central region of Iran.

METHODS

This population-based cross-sectional study was conducted in 2010–2011 on adults aged 40–80 years in both urban and rural area of Yazd district. Yazd is located in central Iran and has an estimated population of 526,000 people according to the 2006 national census. The study adhered to the Declaration of Helsinki and was approved by the Ethics Committee at Shahid Beheshti University of Medical Sciences. All eligible subjects signed an informed consent. The study protocol has been reported in detail previously.[10] In brief, a final sample of 2,023 individuals who belonged to 58 clusters each, containing 40 subjects were selected applying multistage systematic cluster sampling method and with probability proportional to size strategy. Three trained health teams performed subject recruitment by house-to-house visits. Demographic information was collected using a questionnaire, including age, sex, level of education, past ocular and medical history. Individuals were invited to an equipped eye clinic within a week.

Ophthalmic Examination

At the eye clinic, participants underwent a comprehensive eye evaluation. After visual acuity (VA) measurement and refraction, an expert ophthalmologist performed ocular examination including intraocular pressure measurement, gonioscopy, anterior segment examination and anterior chamber depth assessment. The lens and optic disc were examined after dilating the pupil. A trained optometrist performed stereoscopic fundus photography following pupil dilation in all participants and after laser peripheral iridotomy in subjects with an occludable angle. Visual fields of all participants were tested before dilation.

Visual Acuity Testing

Visual acuity was determined using an NIDEK chart projector (CPe670, 20/10–20/400; Nidek Co., Gamagori, Japan) with tumbling E letters at 4 m distance by an experienced optometrist. An Individual, who could not read the largest E letters on the chart was tested for counting fingers, hand motion and light perception. Uncorrected VA and best-corrected VA were evaluated separately for each eye. Refraction was performed using a Topcon KR 8000 automated refractometer (Topcon Co., Tokyo, Japan). If autorefraction was not possible, objective retinoscopy and subjective refraction would be tried.

Definitions

Blindness was defined as VA <3/60 (20/400, 1.3 LogMar) with best correction in the better eye, and low vision was defined as VA <6/18 (20/60, 0.5 LogMar) but equal to or better than 3/60 (20/400, 1.3). VI (included blindness and low vision) was defined as best-corrected VA <6/18 (20/60, 0.5 LogMar) in the better eye. Moderate visual impairment (MVI) and severe visual impairment (SVI) were classified as best-corrected VA <6/18–6/60 and VA <6/60–3/60, respectively.[11] Cataract density was scored using the grading system of the Age-Related Eye Disease Study.[12] Glaucoma was diagnosed using the International Society of Geographical and Epidemiological Ophthalmology classification.[13] Diabetic Retinopathy was assessed by masked grading of stereoscopic fundus photographs using the Early Treatment Diabetic Retinopathy Study definitions[14] and Severity of Diabetic Retinopathy was classified according to the International Clinical Diabetic Retinopathy Disease Severity Scale.[15] Age-related macular degeneration (ARMD) was evaluated based on the International ARMD Epidemiological Study Group.[16] All clinical and paraclinical data were evaluated separately and construed by the study team based on the above definitions and archived in a computer database at the Ophthalmic Research Center. The principle cause of VI or blindness was determined by a reading group which consisted of three retinal and three glaucoma subspecialists with acceptable inter- and intra-reliabilities (based on a Kappa test) according to clinical history and examination of the better eye.[17] If VA improved to 20/60 or better with optical correction, refractive error was considered as the main cause of blindness or VI. In case there was more than one cause for VI and blindness, the most treatable or preventable one was assessed as the main cause of VI and blindness.

Statistical Analysis

Statistical analysis was performed using STATA software version 12.0 (State Corp LP, College Station, TX, USA). The prevalence of VI and blindness was calculated and standardized for age and sex in Yazd based on the 2006 national census. Multiple multinomial logistic regression models were applied to investigate the association between VI and blindness with age, sex, area of residence and education. In analyses, we regarded the cluster effect of sampling for calculating 95% confidence intervals (95% CIs) by multilevel models. In this analysis, we considered two levels (for subject results) and three levels (for eye results). P value less than 0.05 were considered as statistically significant.

RESULTS

Among 2,320 eligible people, 2,098 subjects participated in the study (response rate, 90.4%) and VA data was available for 2,023 (87.2%) individuals. Mean age in the study population was 59.8 ± 6.8 years consisting of 55.5% (1,083) female subjects. Table 1 demonstrates demographics of the study population.
Table 1

Demographic data of study population and participants in the Yazd Eye Study

Demographic data of study population and participants in the Yazd Eye Study The prevalence of blindness and VI were 0.7% (95% CI, 0.3–1.0%) and 4.9% (95% CI, 3.3–5.4%), respectively. These values were higher in female subjects. Table 2 shows the prevalence of VI, blindness and low vision in Yazd district population. Figure 1 displays the cumulative age and sex stratified distribution of blindness, MVI and SVI, suggesting that the severity of visual abnormalities was greater in older individuals and women. VI was more prevalent in older subjects and increased with each decade of older age (odd ratio [OR] =3.1, 95% CI: 2.3–4.2%, P < 0.0001) and was also associated with female gender (OR = 1.7, 95% CI: 1.2–2.5, P = 0.008). Similarly, blindness was associated with each decade of older age (OR = 3.2, 95% CI: 1.9–5.2%, P < 0.0001) and female gender (OR = 3.6, 95% CI: 1.1–12.3%, =0.041). Area of residence or education was not significantly associated with VI and blindness. However, low vision was more prevalent among rural residents (OR = 2.3, 95% CI: 1.2–4.2%, P = 0.009) [Table 3].
Table 2

Prevalence of VI, blindness and low vision based on best corrected visual acuity

Figure 1

Cumulative age and sex distribution for moderate visual impairment (MVI), severe visual impairment (SVI) and blindness in Yazd Eye Study. Blindness = visual acuity <3/60, MVI = visual acuity <6/18 - 6/60; SVI = visual acuity < 6/60 - 3/60.

Table 3

Distribution and comparison of VI, blindness and low vision by age, sex, area and education in the Yazd Eye Study

Prevalence of VI, blindness and low vision based on best corrected visual acuity Cumulative age and sex distribution for moderate visual impairment (MVI), severe visual impairment (SVI) and blindness in Yazd Eye Study. Blindness = visual acuity <3/60, MVI = visual acuity <6/18 - 6/60; SVI = visual acuity < 6/60 - 3/60. Distribution and comparison of VI, blindness and low vision by age, sex, area and education in the Yazd Eye Study Table 4 presents major causes of blindness and VI. Based on best-corrected visual acuity (BCVA), the leading causes of blindness were diabetic retinopathy (50%) followed by glaucoma (21.4%) and cataracts (14.3%). Major causes of VI were cataracts (41.5%), diabetic retinopathy (17%) and age-related macular degeneration (ARMD, 13.8%). Most causes of blindness and VI were avoidable; 92.9% (95% CI: 80–100%) and 76.6% (95% CI: 69.2–85%), respectively [Figure 2]. Causes of blindness were curable and preventable in 14.3% (95% CI: 0–33.4%) and 78.6% (95% CI: 56.7–100%) of cases, while causes of VI were curable or preventable in 44.7% (95% CI: 34.8–53.8%) and 31.9% (95% CI: 22.7–43%) of cases, respectively.
Table 4

Main causes of bilateral blindness and VI based on best corrected VA in the Yazd Eye Study

Figure 2

Distribution of avoidable and non-avoidable causes of blindness and visual impairment in the Yazd Eye Study.

Main causes of bilateral blindness and VI based on best corrected VA in the Yazd Eye Study Distribution of avoidable and non-avoidable causes of blindness and visual impairment in the Yazd Eye Study.

DISCUSSION

The present study highlighted cataracts, diabetic retinopathy and ARMD as the leading causes of VI in Yazd district. The current study is the first survey on the prevalence and causes of VI in the central region of Iran. The standardized prevalence of blindness and VI among adults aged 40 to 80 years was 0.7% and 4.4%, respectively. These figures are comparable to those from Eastern Mediterranean countries.[18] The prevalence of blindness in our study was close to that reported from Saudi Arabia[19] and relatively lower than Africa (Nigeria,[20] Sudan,[21] Malawi)[22] Latin America (1.1% in Argentina to 4.2% in Venezuela)[2324], Middle East region (Pakistan),[25] some Asian countries (Tibet,[26] China,[27] Sri Lanka[28]) and the Western Pacific region (Fiji).[29] In comparison with the current study, studies conducted in Iceland,[30] Los Angeles,[31] Japan[32] and the Indian population of Singapore[33] revealed lower rates of blindness and VI [Table 5].
Table 5

Prevalence of blindness, visual impairment and their causes in some population based studies

Prevalence of blindness, visual impairment and their causes in some population based studies Previous Iranian studies from Varamin (≥50 years, 1.33%),[5] Khuzestan (>5 years, 1.3%)[9] and Zahedan (≥10 years, 0.79%)[8] have reported higher rates of blindness and VI, whereas Tehran (0.28%)[6] and Shahroud (0.3%)[7] studies demonstrated lower rates. Although the overall rate of blindness seems lower in Tehran, this rate was much higher (2.8%) in people aged >60 years. Tehran Eye Study evaluated all age groups, and the Shahroud study invited subjects aged 40–64 years whereas in our study individuals 40 to 80 years of age were included. Moreover, the study populations of Tehran and Shahroud studies were urban residents of the cities, while the population of Yazd Eye Study belonged to both urban and rural areas. The prevalence of blindness and VI were significantly associated with older age and female gender in the current study. The majority of diseases leading to blindness and VI occur in older subjects. The longer life expectancy of female subjects together with less access to healthcare as compared to male individuals may increase the probability of being visually impaired or blind in women. This finding was supported by several studies.[78202527] However, some studies showed this association only in older subjects.[92933353637] There are also exceptions. Rapid assessment of avoidable blindness findings from Malawi demonstrated a higher prevalence of blindness in men as compared to women.[22] This trend was explained by poor outcomes after ocular surgery in that region, because in Malawi, men had more access to cataract surgery than women. The higher prevalence of low vision in rural areas probably indicates that rural residents have improper access to eye care services and/or less knowledge about eye health. This finding was in agreement with the Pakistan eye study.[25] On the other hand, some other studies reported that rural/urban domicile is not a risk factor for blindness, VI or low vision.[92029] Refractive errors have been accounted as a primary cause of VI and blindness in recent studies based on presenting VA.[569193638] Another report from the current study database has reported prevalence of refractive errors in Yazd district.[39] Based on uncorrected visual acuity, refractive errors were the main cause of VI and blindness in our study (85% and 47%, respectively). In contrast to other studies from other regions of Iran and most developing countries, diabetic retinopathy was the main cause of blindness in the present study. Although our analysis was done based on BCVA and we therefore bypassed refractive errors as the main cause of blindness, we did not expect diabetic retinopathy to be a major cause of blindness in Yazd; however, this finding is probably due to the large number of diabetic patients in the region. Screening programs and public education should be seriously performed to prevent and monitor diabetes mellitus in Yazd. Glaucoma is the second cause of blindness worldwide[2] and some developed countries, such as Japan and Germany, have reported glaucoma as the second cause of VI.[3540] It has been estimated that half of the world's population with glaucoma reside in Asia.[41] A previous report from this population based survey demonstrated that 4.4% of Yazd population were affected with glaucoma.[17] According to the present paper, glaucoma was recognized as the second leading cause of blindness. Since glaucoma leads to irreversible blindness, early diagnosis of the disease is essential to prevent vision loss. Several studies in Africa, Asia and Latin America have reported cataracts as the principal cause of blindness and VI.[56789212326333637] Cataracts account for half of the blindness despite the fact that the condition is curable.[218] Cataracts were the third leading cause of blindness in our study. The large number of patients with diabetic retinopathy in Yazd district most likely led to underrepresentation of cataracts as a major cause of blindness. Improving disease awareness through regular check-ups and enhancing the cataract surgery coverage will avoid related blindness. In Western populations, age-related macular degeneration has been the main cause of blindness and VI in white people,[2130] whereas cataracts, diabetic retinopathy and glaucoma are major causes in black people.[21] In the current study, ARMD was the third cause of VI. Trachoma was not a leading cause of visual disability in the current study, however it was recognized as the second cause of blindness in Eastern Mediterranean countries.[18] In some African countries, trachoma has been almost as common as cataracts and considered as the leading cause of blindness and VI.[21] According to previous studies in Iran, VI and blindness are no longer attributed to corneal disorders.[5679] In the current study, we employed BCVA to define blindness and VI, thus the role of refractive errors as a prevalent avoidable cause of VI could not be estimated. Nevertheless, the proportion of avoidable causes of blindness and VI were 92.9% (95% CI: 80–100%) and 76.6% (95% CI: 69.2–85%), respectively. The large proportion of preventable causes of blindness (78.6%; 95% CI: 56.7–100%) in this study, suggests that educational programs may increase community awareness and accordingly encourage proper behaviors for prevention of blindness. Furthermore, 44.7% (95% CI: 34.8–53.8%) of VI causes were curable. Among treatable causes, cataracts had the greatest share in VI. The limitation of our study was not considering presenting VA in defining blindness and VI. On the other hand, the high response rate (90.4%), including participants from both urban and rural areas, and applying fundus images are advantages of this study. In summary, the overall prevalence of blindness and VI was 0.7% and 4.4%, respectively in Yazd district. Major causes of blindness were diabetic retinopathy, glaucoma and cataracts. The main causes of VI were cataracts followed by diabetic retinopathy and ARMD. Educational and screening programs for early detection, follow-up and management of diabetic retinopathy, glaucoma and cataract at the community level are required to eliminate blindness in central Iran. In addition, since the proportion of blindness and irreversible low vision was considerable, it may be recommended that low vision and rehabilitation services be assessed in this district and in case of inadequacy, get improved.

Financial Support and Sponsorship

Research and Technology Department of the Ministry of Health.

Conflicts of Interest

There are no conflicts of interest.
  39 in total

1.  Prevalence and causes of low vision and blindness in a rural Southwest Island of Japan: the Kumejima study.

Authors:  Yuko Nakamura; Atsuo Tomidokoro; Shoichi Sawaguchi; Hiroshi Sakai; Aiko Iwase; Makoto Araie
Journal:  Ophthalmology       Date:  2010-06-29       Impact factor: 12.079

2.  Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1991-05       Impact factor: 12.079

Review 3.  Global estimates of visual impairment: 2010.

Authors:  Donatella Pascolini; Silvio Paolo Mariotti
Journal:  Br J Ophthalmol       Date:  2011-12-01       Impact factor: 4.638

4.  Cataract classification using serial examinations in the age-related eye disease study: age-related eye disease study report no. 24.

Authors:  Robert D Sperduto; Traci E Clemons; Anne S Lindblad; Frederick L Ferris
Journal:  Am J Ophthalmol       Date:  2008-01-16       Impact factor: 5.258

Review 5.  Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales.

Authors:  C P Wilkinson; Frederick L Ferris; Ronald E Klein; Paul P Lee; Carl David Agardh; Matthew Davis; Diana Dills; Anselm Kampik; R Pararajasegaram; Juan T Verdaguer
Journal:  Ophthalmology       Date:  2003-09       Impact factor: 12.079

6.  The prevalence and causes of visual impairment in Tehran: the Tehran Eye Study.

Authors:  A Fotouhi; H Hashemi; K Mohammad; K H Jalali
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

7.  The Yazd Eye Study-a population-based survey of adults aged 40-80 years: rationale, study design and baseline population data.

Authors:  Marzieh Katibeh; Hossein Ziaei; Mohammad Pakravan; Mohammad H Dehghan; Alireza Ramezani; Haydar Amini; Shahin Yazdani; Reza Solaimanizad; Mehdi Yaseri; Mohammad Ali Javadi
Journal:  Ophthalmic Epidemiol       Date:  2013       Impact factor: 1.648

8.  Prevalence of blindness and visual impairment in Nigeria: the National Blindness and Visual Impairment Study.

Authors:  Fatima Kyari; Murthy V S Gudlavalleti; Selvaraj Sivsubramaniam; Clare E Gilbert; Mohammed M Abdull; Gabriel Entekume; Allen Foster
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-12-30       Impact factor: 4.799

9.  Prevalence and risk factors for eye diseases, blindness, and low vision in Lhasa, Tibet.

Authors:  Gui-Qin Wang; Zong-Xi Bai; Jing Shi; Sang Luo; Hong-Fa Chang; Xiao-Yong Sai
Journal:  Int J Ophthalmol       Date:  2013-04-18       Impact factor: 1.779

10.  Prevalence and causes of blindness and low vision in khuzestan province, iran.

Authors:  Mostafa Feghhi; Gholamreza Khataminia; Hossein Ziaei; Mahmood Latifi
Journal:  J Ophthalmic Vis Res       Date:  2009-01
View more
  14 in total

1.  Retinoid analogs and polyphenols as potential therapeutics for age-related macular degeneration.

Authors:  Tanu Parmar; Joseph T Ortega; Beata Jastrzebska
Journal:  Exp Biol Med (Maywood)       Date:  2020-05-21

2.  Ocular manifestation and their associated factors among HIV/AIDS patients receiving highly active antiretroviral therapy in Southern Ethiopia.

Authors:  Anteneh Amsalu; Kindie Desta; Demiss Nigussie; Demoze Delelegne
Journal:  Int J Ophthalmol       Date:  2017-05-18       Impact factor: 1.779

3.  Visual acuity of urban and rural adults in a coastal province of southern China: the Fujian Eye Study.

Authors:  Yang Li; Qin-Rui Hu; Xiao-Xin Li; Yong-Hua Hu; Bin Wang; Xue-Ying Qin; Tao Ren
Journal:  Int J Ophthalmol       Date:  2022-07-18       Impact factor: 1.645

4.  Diabetic Retinopathy Clinical Practice Guidelines: Customized for Iranian Population.

Authors:  Zhale Rajavi; Sare Safi; Mohammad Ali Javadi; Mohsen Azarmina; Siamak Moradian; Morteza Entezari; Ramin Nourinia; Hamid Ahmadieh; Armin Shirvani; Saeid Shahraz; Alireza Ramezani; Mohammad Hossein Dehghan; Mohsen Shahsavari; Masoud Soheilian; Homayoun Nikkhah; Hossein Ziaei; Hasan Behboudi; Fereydoun Farrahi; Khalil Ghasemi Falavarjani; Mohammad Mehdi Parvaresh; Hamid Fesharaki; Majid Abrishami; Nasser Shoeibi; Mansour Rahimi; Alireza Javadzadeh; Reza Karkhaneh; Mohammad Riazi-Esfahani; Masoud Reza Manaviat; Alireza Maleki; Bahareh Kheiri; Faegheh Golbafian
Journal:  J Ophthalmic Vis Res       Date:  2016 Oct-Dec

Review 5.  Prevalence and Major Causes of Visual Impairment in Iranian Adults: A Systematic Review.

Authors:  Seyed-Farzad Mohammadi; Ghasem Saeedi-Anari; Elham Ashrafi; Seyed-Mehrdad Mohammadi; Farshad Farzadfar; Alireza Lashay; Hassan Hashemi
Journal:  Middle East Afr J Ophthalmol       Date:  2017 Jul-Sep

6.  Teleophthalmology in Practice: Lessons Learned from a Pilot Project.

Authors:  Haleh Ayatollahi; Aynaz Nourani; Taleb Khodaveisi; Hossein Aghaei; Mehrdad Mohammadpour
Journal:  Open Med Inform J       Date:  2017-08-22

7.  Visual impairment and blindness in a population-based study of Mashhad, Iran.

Authors:  Hassan Hashemi; Mehdi Khabazkhoob; Mohammad Saatchi; Hadi Ostadimoghaddam; Abbasali Yekta
Journal:  J Curr Ophthalmol       Date:  2017-05-19

Review 8.  Visual Impairment Prevalence, Causes, and Role of Healthcare Access: A Systematic Review and Meta-Analysis in Iran.

Authors:  Mehrdad Afarid; Hossein Molavi Vardanjani; Hamideh Mahdaviazad; Marzieh Alamolhoda; Saman Farahangiz
Journal:  J Ophthalmol       Date:  2020-11-23       Impact factor: 1.909

Review 9.  Frequency of Cataract in Iran: A Meta-Analysis and Systematic Review.

Authors:  Hosien Shahdadi; Mohammad Naim Aminifard; Abbas Balouchi; Hosein Rafiemanesh; Jasem Allahyari
Journal:  Middle East Afr J Ophthalmol       Date:  2018 Jan-Mar

10.  Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agents for Ocular Vascular Diseases: Clinical Practice Guideline.

Authors:  Homayoun Nikkhah; Saeed Karimi; Hamid Ahmadieh; Mohsen Azarmina; Majid Abrishami; Hossein Ahoor; Yousef Alizadeh; Hasan Behboudi; Narsis Daftarian; Mohammad Hossein Dehghan; Morteza Entezari; Fereydoun Farrahi; Heshmatollah Ghanbari; Khalil Ghasemi Falavarjani; Mohammad Ali Javadi; Reza Karkhaneh; Siamak Moradian; Masoud Reza Manaviat; Morsal Mehryar; Ramin Nourinia; Mohammad Mehdi Parvaresh; Alireza Ramezani; Alireza Ragati Haghi; Mohammad Riazi-Esfahani; Masoud Soheilian; Mohsen Shahsavari; Hossein-Ali Shahriari; Zhale Rajavi; Sare Safi; Armin Shirvani; Saeed Rahmani; Hamideh Sabbaghi; Mojgan Pakbin; Bahareh Kheiri; Hossein Ziaei
Journal:  J Ophthalmic Vis Res       Date:  2018 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.